breakout, page-25

Supertramp, the point of this stage of the trial was the dosage, so the big result here was the fact that 800mg was selected as the optimum dose. Avexa do not know the clinical results because the trial is still blinded to them at this stage.

It was not blinded to the Data Monitoring Safety Board (DMSB) though, so the best possible news Avexa could have received was that the trial should continue (indicating the drug was working) and that all participants taking ATC should be moved to the 800mg dose (which is the most suitable dose for fixed dose formulations). The announcement confirmed both of those outcomes were achieved.

It is not possible for them to have granted your wish of announcing a better clinical response because the trial remains blinded to all bar the DMSB. That said, the Phase 2b results showed exactly what you are after because they showed ATC was highly effective in patients resistant to 3TC (the 'old' treatment you refer to). No reason to think the efficacy of ATC will prove to be much different in phase 3.